Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society

Clinical Infectious Diseases

Volumn 31, Issue 2, 2000, Pages 383-421

  Mandell, Lionel A ^a   Marrie, Thomas J ^b   Grossman, Ronald F ^c   Chow, Anthony W ^d   Hyland, Robert H ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEFACLOR; CEFIXIME; CEFOTAXIME; CEFPROZIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CLARITHROMYCIN; CLAVULANIC ACID; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN; SULBACTAM; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ALGORITHM; ANTIBIOTIC THERAPY; ASTHMA; CANADA; CLINICAL TRIAL; DEMENTIA; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSTITUTIONALIZATION; MEDICAL SOCIETY; PENICILLIN RESISTANCE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMONIA; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL;

EID: 0034456999     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313959     Document Type: Review

References (231)

1. Antimicrobial treatment of community acquired pneumonia in adults a conference report
2. American Thoracic Society guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
3. Community-acquired pneumonia in adults: Guidelines for management
4. The periodic health examination. I. Introduction
5. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
6. Economic costs of respiratory tract infections in the United States
7. National hospital discharge survey: Annual summary 1990
8. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975
9. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland
10. Risk factors for pneumonia in the elderly
11. Epidemiology of invasive Streptococcus pneumoniae infections in adults in Finland
12. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94
13. Epidemiology of invasive pneumococcal disease in southern California: Implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial
14. Pneumococcal bacteremia in hospitalized Israeli adults: Epidemiology and resistance to penicillin
15. Risk factors for acquiring pneumococcal infections
16. Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention
17. Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type I infection: Implications for rational empiric antibiotic therapy
18. Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection
19. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail
20. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chronic-care facilities - Massachusetts, October 1995. Oklahoma, February 1996 and Maryland, May-June 1996
21. An outbreak of pneumococcal pneumonia in two men's shelters
22. Surveillance for legionnaires' disease: Risk factors for morbidity and mortality
23. Community-acquired pneumonia requiring hospitalization: 5-year prospective study
24. Prognosis and outcomes of patients with community-acquired pneumonia
25. Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiographic investigations
26. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland
27. Microbial etiology of acute pneumonia in hospitalized patients
28. Community-acquired pneumonia: Impact of immune status
29. Bacteria, viruses, and mycoplasmas in acute pneumonia in adults
30. The characteristics and mortality of outpatient pneumonia
31. Management of pneumonia in the prospective payment era: A need for more clinician and support service interaction
32. The epidemiology of community-acquired pneumonia among hospitalized adults
33. Community-acquired pneumonia in chronic obstructive pulmonary disease: A Spanish multicenter study
34. Reevaluation of the definition of legionnaires' disease: Use of the urinary antigen assay
35. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors
36. Severe community-acquired pneumonia in the elderly: Epidemiology and prognosis
37. Severe community-acquired pneumococcal pneumonia
38. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
39. Respiratory syncytial virus infection in the elderly
40. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly
41. Respiratory syncytial virus is an important cause of community-acquired tower respiratory infection among hospitalized adults
42. Aspiration pneumonia
43. The bacteriology of obstructive pneumonitis: A prospective study using ultrasound-guided transthoracic needle aspiration
44. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases
45. Anaerobic pleuropulmonary infections
46. The triple threat of aspiration pneumonia
47. Anaerobic infections of the lung and pleural space
48. Aetiology of community-acquired pneumonia: A prospective study among adults requiring admission to hospital
49. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia: Comparison between bronchoalveolar lavage and telescoping plugged catheter cultures
50. Chlamydia-like obligate parasite of free-living amoebae
51. Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged
52. Differences in etiology of pneumonias in nursing home and community patients
53. Community-acquired pneumonia the annual cost to the National Health Service in the UK
54. Severe community-acquired pneumonia: Etiology, prognosis and treatment
55. Guidelines for management of adult community-acquired lower respiratory tract infections
56. Overview of community-acquired pneumonia. Prognosis and clinical features
57. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination
58. Observers' errors in taking medical histories
59. The problem of observer variation in medical diagnosis with special reference to chest diseases
60. The epidemiology of acute respiratory infections in children and adults: A global perspective
61. Reliability of eliciting physical signs in examination of the chest
62. Disagreement between observers in an epidemiological study of respiratory disease
63. The stethoscope and roentgenogram in acute pneumonia
64. A prediction rule to identify low-risk patients with community-acquired pneumonia
65. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: An interventional trial
66. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury
67. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia
68. The standardization of bronchoscopic techniques for ventilator-associated pneumonia
69. Pneumonia and ARDS in patients receiving mechanical ventilation: Diagnostic accuracy of chest radiography
70. Accuracy of portable chest radiography in the critical care setting: Diagnosis of pneumonia based on quantitative cultures obtained from protected brush catheter
71. High-resolution computed tomography for the diagnosis of community-acquired pneumonia
72. Interobserver reliability of the chest radiograph in community-acquired pneumonia
73. Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia
74. Interobserver variability in the interpretation of chest roentgenograms of patients with possible pneumonia
75. Accuracy and its relationship to experience in the interpretation of chest radiographs
76. Comparison of physician judgment and decision aids for ordering chest radiographs for pneumonia in outpatients
77. The need for chest roentgenograms in adults with acute respiratory illness: Clinical predictors
78. Prediction of pneumonia in outpatients with acute cough: A statistical approach
79. Clinical criteria for the detection of pneumonia in adults: Guidelines for ordering chest roentgenograms in the emergency department
80. Clinical prediction rule for pulmonary infiltrates
81. Decision rules and clinical prediction of pneumonia: Evaluation of low-yield criteria
82. A prediction rule to identify low-risk patients with community-acquired pneumonia
83. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU
84. The value of routine microbial investigation in community-acquired pneumonia
85. Microscopic and bacteriologic analysis of expectorated sputum
86. Clinical value of paired sputum and transtracheal aspirates in the initial management of pneumonia
87. Sputum Gram's stain in community-acquired pneumococcal pneumonia: A meta-analysis
88. The value of the sputum Gram's stain in community-acquired pneumonia
89. Sputum Gram stain assessment in community-acquired bacteremic pneumonia
90. Etiological diagnosis of bacterial pneumonia by Gram stain and quantitative culture of expectorates. Leukocytes or alveolar macrophages as indicators of sample representativity
91. The diagnostic value of sputum culture in acute pneumonia
92. Accuracy of Gram's stain in identifying pneumococci in sputum
93. Nonvalue of sputum culture in the management of lower respiratory tract infections
94. Rapid identification of pneumococci: Gram stain vs. The quellung reaction
95. Rapid detection of pneumococcal antigens in sputa in patients with community-acquired pneumonia by coagglutination
96. A prospective hospital study of the aetiology of community-acquired pneumonia
97. Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia
98. Community-acquired pneumonia
99. Community-acquired pneumonia
100. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks
101. Blood cultures in adult patients released from an urban emergency department: A 15-month experience
102. Bacteremic community-acquired pneumonia due to viridans group streptococci
103. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin
104. Value of routine microbial investigation in community-acquired pneumonia treated in a tertiary care center
105. A three-year study of severe community-acquired pneumonia with emphasis on outcome
106. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients
107. Rapidly fatal outcome of bacteremic Klebsiella pneumoniae pneumonia in alcoholics
108. Bacteremic pneumococcal pneumonia: A community hospital experience
109. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996: A detailed analysis of 108 cases
110. Recurrent pneumococcal bacteremia: A warning of immunodeficiency
111. Pneumococcal bacteremia with pneumonia: Mortality in acquired immunodeficiency syndrome
112. The reliability of sputum typing and its relations to serum therapy
113. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia
114. A criterion based audit of community-acquired pneumonia
115. Invasive diagnostic techniques in pulmonary infections
116. Diagnosis of bacterial pulmonary infections with quantitative protected catheter cultures obtained during bronchoscopy
117. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture
118. Serological diagnosis of Mycoplasma pneumoniae infections: A critical review of current procedures
119. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen
120. Parapneumonic effusions
121. Management of complicated parapneumonic effusions
122. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia
123. Empyema thoracis during a ten-year period: Analysis of 72 cases and comparison to a previous study (1952 to 1967)
124. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia
125. Community-acquired pneumonia factors influencing intensive care admission
126. The hospital admission decision for patients with community-acquired pneumonia: Results from the pneumonia Patient Outcomes Research Team cohort study
127. The hospital discharge decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study
128. Clinical pathways in an acute care setting: Community-acquired pneumonia
129. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
130. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia
131. Severe community-acquired pneumonia: Assessment of severity criteria
132. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System
133. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta
134. Susceptibitity of pneumococci to nine antibiotics
135. World-wide development of antibiotic resistance in pneumococci
136. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea
137. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
138. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract
139. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1977 results from the SENTRY Antimicrobial Surveillance Program
140. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae
141. Cross-Canada surveillance susceptibility testing of Haemophilus influenzae with β-lactams, trimethoprim/sulfamethoxazole, and clarithromycin
142. A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens
143. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study
144. The growing threat of penicillin-resistant Streptococcus pneumoniae
145. Resistance issues and treatment implications: Pneumococcus, Staphylococcus aureus and gram negative rods
146. Impact of antibiotic resistance on chemotherapy for pneumococcal infections
147. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study
148. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae
149. Antibiotics for community-acquired respiratory tract infections: Are the benefits worth the risks?
150. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia
151. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
152. Infections caused by erythromycin-resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study
153. Breakthrough sepsis in macrolide-resistant pneumococcal infection
154. Intrapulmonary steadystate concentrations of clarithromycin and azithromycin in healthy adult volunteers
155. The Canadian Bacterial Surveillance Network. Cross-Canada surveillance of drug-resistant Streptococcus pneumoniae (DRSP) from 1988 to 1996
156. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinotones in Canada
157. Streptococcus pneumoniae resistance to fluoroquinolones
158. Comparison of oral cephalosporins and their activity against β-lactamase-producing bacteria
159. Changing nature of bacteria causing adult upper and lower respiratory tract infections: Focus on β-lactamase-producing bacteria
160. Antibiotic therapy for community-acquired pneumonia
161. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli
162. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation
163. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia
164. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
165. Implications for macrolide treatment in community-acquired pneumonia
166. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection
167. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
168. Clarithromycin versus amoxicillin - Clavulanic acid in the treatment of community-acquired pneumonia
169. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia
170. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin - Clavulanic acid and erythromycin
171. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia
172. Oral empiric treatment of community-acquired pneumonia: A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin
173. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
174. Comparison of grepafloxacin (GFX) with clarithromycin (CLA) in the treatment of conmmnity-acquired pneumonia (CAP)
175. Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia (CAP)
176. A double blind, randomized multicenter study in ambulatory community-acquired pneumonia (CAP) comparing trovafloxacin with clarithromycin
177. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia
178. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia
179. Bacteremic pneumococcal pneumonia: Still due to penicillin-susceptible strains in Canada
180. The quinolones: History and overview
181. Clinical role of fluoroquinolones in patients with respiratory tract infections
182. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
183. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
184. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
185. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia
186. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
187. Comparative study of levofloxacin (LVFX) and co-amoxiclav (C0-AC) in the treatment of community-acquired pneumonia (CAP) in adults
188. Comparison of grepafloxacin with cefaclor in the treatment of community-acquired pneumonia
189. A double-blind, randomized, multicenter, global study in trovafloxacin with ceftriaxone plus erythromycin
190. The first comparative study with levofloxacin: A double-blind comparative study of gatifloxacin, a new quinolone, and levofloxacin in pneumonia
191. Fluoroquinolones and respiratory tract infections: Do they work?
192. The new fluoroquinolones: A critical review
193. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections
194. Cefuroxime compared to amoxicillin - Clavulanic acid in the treatment of community-acquired pneumonia
195. Pharmacoeconomic benefit of antibiotic stepdown therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil
196. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia
197. A prospective randomized study of inpatient i.V. Antibiotics for community-acquired pneumonia: The optimal duration of therapy
198. Evaluation of a pneumonia practice guideline in an interventional trial
199. Sequential intravenous/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia
200. Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: Open, randomized controlled trial
201. Cefuroxime efficacy in pneumonia: Sequential short-course i.V./oral suspension therapy
202. Parenteral-oral switch in the management of paediatric pneumonia
203. Sequential therapy in the hospital management of lower respiratory infections
204. Antibiotic therapy in pneumonia: A comparative study of parenteral and oral administration of penicillin
205. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia
206. Oral ofloxacin for the treatment of acute bacterial pneumonia: Use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial
207. Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia
208. Pneumonia in residents of long-term care facilities: Epidemiology, etiology, management, and prevention
209. Does appropriate antibiotic treatment influence outcome in community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB)?
210. Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum β-lactams, and aminoglycosides and susceptibility to antibiotic combinations
211. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology
212. Assessment of response to antimicrobial therapy and time to discharge in patients hospitalized with community-acquired pneumonia
213. Etiology of community-acquired pneumonia in out-patients
214. Prospective study on community-acquired pneumonia diagnosed and followed up by private practitioners: CHUV, Lausanne, Switzerland
215. Serological investigation of pneumonia as it presents to the physician's office
216. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens
217. The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia
218. Pneumonia in a nursing home
219. Interim report on drug utilization review of community-acquired and nosocomial pneumonia: Clinical, bacteriological and radiological spectrum
220. Serological study of responses to selected pathogens causing respiratory tract infection in the institutionalized elderly
221. The aetiology, management and outcome of severe community-acquired pneumonia in the intensive care unit
222. A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission
223. Severe community-acquired pneumonia: Factors influencing need of intensive care treatment and prognosis
224. Severe community-acquired pneumonia. Epidemiology and prognostic factors
225. Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors, and outcome
226. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
227. Prevention of pneumococcal disease
228. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
229. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization (ACIP)